Articles On Recce Pharmaceuticals (ASX:RCE)

Highlights: Recce Pharmaceuticals initiates a two-part capital raise to support advanced clinical trials Funding allocated to clinical programs focused on diabetic foot and bacterial skin infections Trials to be conducted ac...

Recce Pharmaceuticals Ltd (ASX:RCE) is aiming to complete a capital raising of $15.8 million to funds its clinical trials in Indonesia and Australia through a $5M Placement to a private investor and $10.8M Entitlement Offer to shareholders....

Funding to support Phase III clinical trials for diabetic foot infections and acute bacterial skin and skin structure infections Private Australian-based investor has subscribed for $5 million shares via a placement A$10.8 million entitlem...

Nova Eye and Syntara led today’s biotech relief rally, after the sector sunk on Wednesday on the back of a flagged US pharmaceutical tariff Flu vaccines don’t give you autism, but do they work? Recce is raising up to $15.8 million to fund...

A ginger group of Mayne Health shareholders argues Cosette’s $600 million offer isn’t the right prescription Artrya gets to the heart of the matter after FDA approval Zelira Therapeutics goes to the ATM for $1 million   US healthcare grou...

Superbug-buster Recce has bucked the trend by targeting Indonesia as the host of its planned phase III diabetic foot ulcer trial Recce’s synthetic antibiotic candidate seeks to overcome the problem of antimicrobial resistance A local phase...

ASX slides again, seven losses in eight days Copper tariff talk spooks miners, Rio and BHP down Woolies, Platinum, and Flight Centre also take a hit   It was another rocky ride for local stocks today, with the ASX 200 benchmark down by 0....

Banks drag as Bendigo, Westpac slump Star Entertainment Group jumps on $650m refinancing Jack Ma’s return sparks tech rally in China   The ASX retreated by about 0.37% from Friday’s record high, with banks pulling the market down on Monda...

Recce Pharmaceuticals (ASX: RCE) has released positive patient data analysis from a Phase II clinical trial of its Recce 327 topical gel (R327G) for the treatment of acute bacterial skin and skin structure infections. The company designed t...

A successful phase II clinical trial has taken place, assessing efficacy and safety of R327G in patients with acute bacterial skin and skin structure infections Recce said objectives exceeded with a 93% primary efficacy endpoint achieved f...

Recce Pharmaceuticals Ltd (ASX:RCE) has yielded positive data on the effectiveness of its topical gel in treating Acute Bacterial Skin and Skin Structure Infections, including patients with Diabetic Foot Infections, with a primary efficacy...

Dimerix forecasting second interim analysis of its ACTION3 phase III trial mid CY25 Retinal-diseases-focused biotech Opthea is awaiting two trial results in CY25 Recce set to start trial assessing topical gel to treat diabetic foot infecti...

The ASX200 has been up 0.5% at 8,445 points. Just after the local bourse opened, Trump says the U.S. is seriously considering tariffs on China due to the alleged production and distribution of fentanyl. IT has been the best performing...

ASX reverses after Trump’s tariff threat sends jitters Bitcoin drops as Trump’s policies remain unclear Hub24 shines, Santos slumps after project delay   After an upbeat start to the day, the S&P/ASX 200 Index, which had surged as muc...

Recce Pharmaceuticals Ltd (ASX:RCE) has seen its share price move up more than 1% on Tuesday’s news that the company successfully dosed all 30 participants in its Phase II clinical trial of a gel to treat skin infections. The trial – who...

RCE has dosed all patients in phase II trial of R327G treatment for skin infections Company says market valued at US$26bn globally Results pending ahead of planned phase III trial   Special Report: Recce Pharmaceuticals has wrapped up dos...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Research reports on ASX-listed companies, to download in full. **** -Airtasker ((ART...

Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead. In this episode, Sarah Hughan explores Recce Pharmaceuticals (ASX:RCE) and a series of succes...

Sydney-based Recce Pharmaceutical Ltd (ASX:RCE) has reached a landmark stage in its bid to commercialise a topical gel that would treat diabetic foot infections (DFIs), gaining approval for a Phase 3 trial in Indonesia to assess the gel in...

ASX drops as Trump’s tariff threat rattles markets Bluescope and Reece rise amid energy and bank sell-off EML Payments jumps after strong earnings report   The ASX closed in the red on Tuesday, down by 0.45% after being dragged down by a...

Recce Pharmaceuticals Ltd (ASX:RCE) has ticked off completion of all patents for two of its key anti-infectives, with the Australian Patent Office granting ‘Patent Family 3’ status to RECCE 327 (R327) and RECCE 529 (R529). The latest pat...

World Antimicrobial Resistance Awareness Week aims to put a spotlight on growing threat of antimicrobial resistance  Recce is tackling the global health problem of antibiotic-resistant superbugs with its new class of synthetic anti-infecti...

ASX up, Xero leads gains Miners hit as iron ore drops, Variscan jumps 50pc Asian stocks down, Bitcoin hits US$93k before retreating   Aussie shares climbed higher on Thursday, powered by a rally in tech companies and the big banks. At the...

Recce Pharmaceuticals (ASX:RCE) has received a $6.75 million Research and Development (R&D) Tax Incentive rebate from the Australian Taxation Office for FY24. This receipt was used to repay advances from Endpoints Capital reflectin...

ASX starts week lower with mining stocks under pressure Resolute mining plunges after CEO detained in Mali Bitcoin surges past US$81k as Trump’s win fuels optimism   The ASX had a rough start to the week, with mining stocks dragging the m...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Sarah Hughan tells all on Recce Pharmaceuticals’ (ASX:RCE) approval from the Indonesian Government for a phase 3 clinical trial of i...

The ASX200 closed down 0.4% at 8,131 points. The Reserve Bank Board has kept interest rates on hold at 4.35% in line with consensus expectations. RBA Governor Michelle Bullock says the bank wants to be more convinced inflation is going t...

Aussie shares slip as RBA holds rates steady MinRes rebounds, Domino’s Don Meij quits Investors rethink Trump comeback as Harris leads in Iowa   Aussie shares slipped into the red on Tuesday, falling 0.4% as sentiment remained subdued aft...

Recce Pharmaceuticals is nearing completion in its Phase II clinical trial for acute bacterial skin and skin structure infections The study is designed to evaluate the efficacy of topical gel RECCE® 327 (R327G) It is designed to treat dia...

Non-DSMB unanimously agree Recce’s topical gel R327G is safe and well-tolerated in patients with acute bacterial skin and skin-structure infections R327G demonstrates highly encouraging efficacy results with all patients completing treatme...

  ASX closes  higher with consumer and utilities leading the charge Wall Street rally boosts sentiment as Nvidia jumps 4pc China’s CSI 300 index falls 5pc amid doubts over stimulus plans   The ASX closed 0.13% higher on Wednesday, thanks...

Recce Pharmaceuticals Ltd (ASX:RCE) has reached the halfway mark in dosing participants in its Phase II Acute Bacterial Skin and Skin Structure Infections (ABSSSI) clinical trial. The company has dosed 15 patients in the trial so far, wh...

Echo IQ shares soar after the FDA approves its aortic stenosis diagnosis. Pacific Edge’s cancer diagnostic revenues hold up despite US reimbursement doubts Recce Pharmaceuticals reaches halfway mark in phase II germ-busting trial   Health...

For those not regular watchers of the ASX biotech sector, it’s worth noting Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. Recce is developing its flagship patented next-gen anti-infective, R327, with clinical results so f...

Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode, Tim chats with Recce Pharmaceuticals (ASX:RCE) managing director and CEO James Graham. Cracking the...

Southeast Asia presents growth for ASX health stocks with rising aging population and growing middle class EZZ has started selling EAORON branded products in Vietnam and signed Australian Open sponsorship deal  Recce has signed a MoU with...

Antimicrobial resistance is among the most significant threats to public health and development, says WHO Recce Pharmaceuticals is tackling the global health problem of antibiotic-resistant superbugs It has a military reconnaissance appro...

The ASX200 has hit a fresh all time high of 8,035 points in buoyant Monday trade with the market up 0.8% heading into 1pm. Investors are speculating the Federal Reserve in the United States could launch its rate cutting cycle with a 50 b...

Synthetic anti-infective developer Recce Pharmaceuticals Ltd (ASX:RCE) has made inroads for recognition of its RECCE® 327 Gel (or R327G) as a topical treatment for burn wound infections, gaining a US$2 million grant from the US Department o...

Keely Lynch: RCE Pharmaceuticals has announced a capital raise following the completion of its phase one and two UTI trial. To discuss this further, I’m joined by the company CEO, James Graham. Welcome James. It’s been a busy few weeks f...

IMM files a pre-IND application with US FDA for IMM-529 targeting common pathogen clostridioides difficile Ansell completes 100% acquisition of the assets of US giant Kimberly-Clark Corporation’s personal protective business Actinogen Xana...

Choppy day leaves the ASX 200 benchmark below zero, down -0.2pc Energy surges on news of a coal fire in Queensland, because that’s good for business everywhere else Small Caps winners’ list dominated by a $12 million boat sale by Wellard,...

The ASX200 closed the week up 0.1%. The IT sector finished on top, gaining 0.9%. Financials followed, gaining 0.75%. Materials took the hardest hit, falling just short of a percent. US Inflation The US will release its latest PCE i...

Sydney-based Recce Pharmaceuticals Ltd (ASX:RCE) has found that its synthetic anti-infective drug RECCE® 327 (or R327) is effective in treating bacterial growth – specifically Escherichia coli (E.coli) – following a Phase I/II clinical tria...

Microba completes program with  Ginkgo Bioworks Recce reports encouraging results from Phase I/II clinical trial Imricor completes second iCMR ablation procedure in Croatia   Microba Life Sciences (ASX:MAP) has announced the successful co...

Despite futures tipping a 0.25% decline on the bourse the market has tanked 1.10% in the first hour of trades. The immediate catalysts at play aren’t obvious but are likely being driven in part by low iron ore prices, stronger than expec...

The ASX200 is trading strongly to start the week, gaining around three quarters of a per cent. While the Real Estate sector has taken the lead, the Energy sector spurred early gains, driven by Strike Energy (ASX:STX), which is up more th...

Recce Pharma (ASX:RCE) has announced it’s further boosting its role as an emerging defence company operating in the US military supply chain. In April this year, the company notified the market it had started applying for a US defence re...

The work of pharmaceutical companies can bring new hope to patients delivering solutions to unmet medical needs. It can also turn a small market cap play into a giant – but it’s a process that’s not easy, it’s risky and it can take a lot of...

Recce Pharma (ASX:RCE) has announced the latest cohort of patients part of the company’s Phase I/II UTI trial has been dosed with the highest ever volume of R327 to date. In the ongoing IV-based trial that seeks to treat urinary tract in...